Mifomet

Metformin Hydrochloride / Sitagliptin, the active ingredient in Mifomet, is a biguanide and DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients.

GNH USA supplies Mifomet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. All batches meet EU quality standards and are manufactured under GMP conditions. The company provides reliable logistics where required and supports regulatory documentation for import.

Mifomet, a combination antidiabetic medication, is used to improve glycemic control in type 2 diabetes mellitus.

- Type 2 diabetes mellitus: lowers HbA1c and fasting plasma glucose levels. - Inadequate control on metformin alone: adds DPP‑4 inhibition to achieve target glucose. - Patients requiring combination therapy: simplifies regimen by combining two agents in one tablet.

Mifomet may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Nausea or abdominal discomfort. - Diarrhea or loose stools. - Headache. - Mild hypoglycemia, especially when used with insulin or sulfonylureas.

Serious or Rare Side Effects: - Lactic acidosis. - Severe hypoglycemia. - Acute pancreatitis. - Allergic skin reactions such as rash or Stevens‑Johnson syndrome. - Hepatic dysfunction. - Renal impairment.

When prescribing Mifomet, clinicians should consider several safety measures.

- Renal function assessment: evaluate creatinine clearance before initiating therapy. - Lactic acidosis risk: avoid in patients with significant renal or hepatic impairment. - Hypoglycemia monitoring: caution when used with insulin or sulfonylureas. - Pregnancy and lactation: use only if benefits outweigh risks. - Drug interactions: review concomitant medications for DPP‑4 inhibitors. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture.

Mifomet can interact with several medicines; interactions are grouped by clinical relevance.

Major Interactions (Avoid): - Concomitant use with strong CYP2C9 inhibitors (e.g., fluconazole) may increase metformin exposure. - Co‑administration with insulin or sulfonylureas can cause severe hypoglycemia. - Renal toxic agents such as iodinated contrast media increase the risk of metformin‑associated lactic acidosis.

Moderate Interactions (Monitor Closely): - Diuretics may reduce renal clearance of metformin, requiring dose adjustment. - Beta‑blockers can mask symptoms of hypoglycemia. - Corticosteroids may diminish the glucose‑lowering effect of the combination. - ACE inhibitors may enhance renal protection but require monitoring of renal function. - Alcohol intake can potentiate metformin‑related lactic acidosis risk.